Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Authors :: Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.
Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.
Source :: Haematologica; e47; e51; 0390-6078; 2; 102; ~Haematologica~e47~e51~~~0390-6078~2~102~~
Publication Year :: 2017
Abstract: Contains fulltext : 169738.pdf (publisher's version ) (Open Access)

Database :: OAIster
Journal :: Haematologica; e47; e51; 0390-6078; 2; 102; ~Haematologica~e47~e51~~~0390-6078~2~102~~
Publication Type :: Electronic Resource
Accession number :: edsoai.on1284147529
Document Type :: Electronic Resource

Tools